# A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension

> **NCT07116863** · PHASE3 · COMPLETED · sponsor: **Kyungdong Pharmaceutical Co., Ltd.** · enrollment: 286 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** KDF1901-R0
- **DRUG:** KDF1901-L
- **DRUG:** KDF1901
- **DRUG:** KDF1901-R1

## Key facts

- **NCT ID:** NCT07116863
- **Lead sponsor:** Kyungdong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-21
- **Primary completion:** 2024-06-20
- **Final completion:** 2024-09-13
- **Target enrollment:** 286 (ACTUAL)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07116863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07116863, "A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07116863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*